Capricor Therapeutics says FDA extends Deramiocel PDUFA target date
Capricor Therapeutics says the FDA has extended the PDUFA target action date for its deramiocel BLA as the review continues.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.